The scientist’s investigation covers issues in Internal medicine, Oncology, Pathology, Cancer research and Fluorescence in situ hybridization. His Internal medicine research is multidisciplinary, relying on both Surgery and Oligodendroglioma. The concepts of his Oncology study are interwoven with issues in Chemotherapy, Breast cancer, Trastuzumab, Guideline and Radiation therapy.
His Pathology research incorporates themes from Chromosome and Prostate. He combines subjects such as Carcinogenesis, Tumor suppressor gene, Gene and Mutation with his study of Cancer research. He usually deals with Fluorescence in situ hybridization and limits it to topics linked to Cytogenetics and Chromosome 7.
Robert B. Jenkins spends much of his time researching Internal medicine, Oncology, Pathology, Cancer research and Glioma. The study of Internal medicine is intertwined with the study of Surgery in a number of ways. His work deals with themes such as Radiation therapy, Chemotherapy, Temozolomide and Prostate cancer, which intersect with Oncology.
His Pathology research includes elements of Fluorescence in situ hybridization, Chromosome, Cytogenetics and Oligodendroglioma. Robert B. Jenkins interconnects Carcinogenesis, Tumor suppressor gene, Mutation, Germline and PTEN in the investigation of issues within Cancer research. His Glioma research focuses on Genome-wide association study and how it connects with Genetic association.
His scientific interests lie mostly in Internal medicine, Oncology, Glioma, Cancer research and Gene. His Oncology research is multidisciplinary, incorporating perspectives in Odds ratio, Clinical Oncology, Temozolomide, Breast cancer and Oligodendroglioma. His Glioma study incorporates themes from Single-nucleotide polymorphism, Genome-wide association study, Genotype and Case-control study.
As a part of the same scientific study, Robert B. Jenkins usually deals with the Cancer research, concentrating on Germline and frequently concerns with Diffuse Glioma. His work carried out in the field of Gene brings together such families of science as Molecular biology and Computational biology. His Prostate cancer study combines topics from a wide range of disciplines, such as Prostate and Metastasis.
His primary areas of investigation include Glioma, Internal medicine, Oncology, Gene and Cancer research. His Glioma study combines topics in areas such as Obesity, Epidemiology, Case-control study, Pathology and Brain tumor. The various areas that Robert B. Jenkins examines in his Pathology study include Chromosome 9 and Distribution.
His biological study spans a wide range of topics, including Guideline and Single-nucleotide polymorphism. His Oncology research incorporates elements of Breast cancer, Human Epidermal Growth Factor Receptor 2, Angiogenesis, Retrospective cohort study and O-6-methylguanine-DNA methyltransferase. His Cancer research study integrates concerns from other disciplines, such as Insertional mutagenesis, Transposon mutagenesis and Carcinogenesis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman.
The New England Journal of Medicine (2005)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett.
Archives of Pathology & Laboratory Medicine (2014)
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
L C Hartmann;D J Schaid;J E Woods;T P Crotty.
The New England Journal of Medicine (1999)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E Eckel-Passow;Daniel H Lachance;Annette M. Molinaro;Kyle M. Walsh.
The New England Journal of Medicine (2015)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman;Philip T. Cagle;Mary Beth Beasley;Dhananjay Arun Chitale.
Journal of Thoracic Oncology (2013)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C. Wolff;M. Elizabeth Hale Hammond;Kimberly H. Allison;Brittany E. Harvey.
Archives of Pathology & Laboratory Medicine (2018)
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross;Meihua Wang;Edward Shaw;Robert Jenkins.
Journal of Clinical Oncology (2013)
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
Justin S. Smith;Arie Perry;Thomas J. Borell;Hyun K. Lee.
Journal of Clinical Oncology (2000)
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross;B. Berkey;Edward G. Shaw;Robert Brian Jenkins.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: